Mitrovic V, Gessner C, Hain P, Müller K D, Schlepper M
Kerckhoff-Klinik of the Max-Planck-Society, Bad Nauheim, Germany.
Clin Cardiol. 1991 Mar;14(3):209-18. doi: 10.1002/clc.4960140307.
In 20 patients with established coronary artery disease, stable angina pectoris and reproducible ST-segment depression, the pharmacokinetics and pharmacodynamic effects of 60 mg slow-release isosorbide-5-mononitrate (IS-5-MN) (10 patients) after a 7-day therapy were compared with those of a placebo group (10 patients) using a randomized double-blind, placebo-controlled study design. Ten patients could be controlled after long-term therapy over a mean of 399 +/- 111 days. There was no significant change under IS-5-MN of either blood pressure, heart rate, rate-pressure product, or myocardial oxygen consumption. Treatment over one week significantly reduced ST-segment depression 4 and 8 h after drug intake (38-48% of the placebo value, p less than 0.01). Maximum reduction in ST-segment depression was found 4 and 8 h after IS-5-MN intake both after one-week and long-term therapy at the time of peak plasma drug concentration (341 +/- 95 and 405 +/- 125 ng/ml, respectively). At a residual plasma concentration below 100 ng/ml, ST depression was not significantly improved 24 h after drug intake compared with placebo. Technetium-99m ventriculography showed an insignificant increase in ejection fraction and a slight reduction of ventricular volumes after both short- and long-term therapy with IS-5-MN (p greater than 0.05). The drug's plasma levels were higher under chronic than under short-term therapy which may be due to enzyme saturation. Maximum IS-5-MN plasma concentrations at a mean of 445 +/- 116 ng/ml were reached after 5.8 +/- 2.9 h. Beta-phase half-life of elimination was 9 +/- 3 h. IS-5-MN administered as a single 60 mg dose of a slow-release preparation/day proved to have a favorable pharmacokinetic profile as well as an efficient antiischemic activity after both short- and long-term therapy. Problems of tolerance or activation of hormonal counter-regulation due to vasodilation were not observed.
在20例确诊为冠状动脉疾病、稳定型心绞痛且ST段压低可重复的患者中,采用随机双盲、安慰剂对照研究设计,比较了10例患者在接受7天治疗后服用60毫克缓释5-单硝酸异山梨酯(IS-5-MN)的药代动力学和药效学效应与安慰剂组(10例患者)的情况。10例患者在平均399±111天的长期治疗后得到控制。IS-5-MN治疗期间,血压、心率、心率-血压乘积或心肌耗氧量均无显著变化。治疗一周后,服药后4小时和8小时ST段压低显著降低(为安慰剂值的38%-48%,p<0.01)。在一周和长期治疗后,IS-5-MN服药后4小时和8小时,即血浆药物浓度峰值时,ST段压低的最大降幅出现(分别为341±95和405±125纳克/毫升)。在血浆残留浓度低于100纳克/毫升时,与安慰剂相比,服药后24小时ST段压低无显著改善。锝-99m心室造影显示,IS-5-MN短期和长期治疗后射血分数增加不显著,心室容积略有减小(p>0.05)。长期治疗时药物的血浆水平高于短期治疗,这可能是由于酶饱和所致。平均5.8±2.9小时后达到最大IS-5-MN血浆浓度,平均为445±116纳克/毫升。消除的β相半衰期为9±3小时。每天服用一次60毫克缓释制剂的IS-5-MN在短期和长期治疗后均显示出良好的药代动力学特征以及有效的抗缺血活性。未观察到因血管扩张导致的耐受性问题或激素反调节激活。